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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not dasatinib 
improves outcomes and tolerability in patients with chronic myeloid leukemia as compared to 
imatinib. 
Study Design:  Review of three English language, non-blinded randomized controlled trials from 
2009, 2010, and 2010. 
Data Sources:  Randomized, controlled, non-blinded clinical trials comparing dasatinib to 
imatinib or comparing dasatinib once daily vs dasatinib twice daily, found using the PubMed 
database. 
Outcomes measured: Overall survival and progression-free survival were measured at one and 
two years after initiation of therapy.  Safety profiles and incidence of adverse effects were also 
measured.  This is graded on a scale of 1 to 4, from lowest in severity to highest in severity.  
Additionally, adverse effects were noted as hematologic (neutropenia, anemia, 
thrombocytopenia) or nonhematologic (fluid retention, diarrhea, vomiting, fever). 
Results:  When comparing dasatinib to imatinib, both drugs provided similar figures for 
progression-free survival (96% vs 97% respectively) and overall survival (97% vs 99% 
respectively).  However, patients taking dasatinib progressed to accelerated or blastic phases of 
CML 1.9% of the time, and those taking imatinib progressed 3.5% of the time.  Dasatinib had 
higher rates of hematologic adverse events, and imatinib had higher rates of nonhematologic 
adverse events. 
When comparing dasatinib 140 mg once daily to dasatinib 70 mg twice daily, the twice daily 
dose produced higher overall survival at 12 months (84% vs 78%) and at 24 months (72% vs 
63%), as well as fewer deaths due to progressive disease (43% vs 52%).  Rates of 
nonhematologic adverse events were similar between the two groups.  However, the once daily 
dose lead to lower incidence of gastrointestinal bleeding (8% vs 13%) and pleural effusion (20% 
vs 39%). 
Conclusions: Dasatinib improves outcomes and tolerability in patients with chronic myeloid 
leukemia as compared to imatinib.  This is advantageous not only considering patient quality of 
life, but also morbidity and mortality from complications such as pleural effusions, congestive 
heart failure, and bleeding.  Additionally, by improving tolerability, patients are less likely to 
discontinue treatment before completion of a full course of therapy. 
Key Words: Chronic myeloid leukemia, dasatinib, imatinib 
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INTRODUCTION 
Chronic myeloid leukemia (CML) is a form of cancer originating in the bone marrow that 
results in increased and unregulated growth of myeloid cells and their precursors.2  It is 
associated with a characteristic translocation on the Philadelphia chromosome.2  Survival has 
increased dramatically since the introduction of tyrosine kinase inhibitors (TKIs) such as 
imatinib (brand name Gleevec) and dasatinib (brand name Sprycel).2 
Imatinib, a first generation TKI, is the standard first-line therapy for patients with CML.3  
Dasatinib, a second generation TKI, has been approved as second-line treatment for patients with 
CML if imatinib therapy fails.3  In patients who fail or are unable to tolerate imatinib therapy, 
dasatinib induces a complete cytogenic response approximately 50% of the time.3 
This paper evaluates three randomized controlled trials comparing the effectiveness and 
tolerability of imatinib and dasatinib. 
Chronic myeloid leukemia has an incidence of 1-2 per 100,000 people, occurring most 
commonly in middle-aged and elderly adults.  This represents 15-20% of all adult leukemia.2  
Ionizing radiation exposure, including radiation treatments used to treat other cancers, is the only 
well-described risk factor for developing CML.2  In 2010, there were 4,870 newly diagnosed 
cases of CML  
Tyrosine kinase inhibitors are the gold standard for treatment of CML.  Imatinib averages 
$3170.40 for a 30 day supply, whereas Dasatinib averages $4676.40.3  While the cost is 
significant, CML that is not treated with a TKI is associated with longer hospital stays and higher 
morbidity.3 
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CML is a bone marrow stem cell disorder that causes proliferation of mature 
granulocytes (neutrophils, eosinophils, and basophils) and their precursors.2  Patients are often 
asymptomatic at diagnosis, presenting incidentally with elevated white blood cell count on 
routine complete blood count.2  Symptomatic patients may present with splenomegaly, malaise, 
arthralgia, low-grade fever, immune compromise, anemia, and thrombocytopenia.2  A 
characteristic genetic abnormality of CML is translocation on the Philadelphia chromosome 
(translocation between chromosomes 9 and 22), resulting in BCR-ABL protein abnormalities.2  
TKIs selectively inhibit the oncogene BCR-ABL, impeding the pathogenesis of CML.2 
Imatinib is a first generation TKI that is proven to increase overall survival in CML.3  
Dasatinib is a second generation TKI that may have higher overall survival in CML compared to 
imatinib, as well as a more favorable safety profile.3 
OBJECTIVE 
The objective of this systematic review is to determine whether or not dasatinib improves 
outcomes and tolerability in patients with chronic myeloid leukemia as compared to imatinib. 
METHODS 
 All three randomized controlled trials utilized for this review were selected because their 
population group included chronic myeloid leukemia patients greater than 18 years of age.  Two 
of the studies utilized patients who had shown resistance or intolerance to imatinib.  In these 
studies, one group of patients would receive dasatinib 140 mg once daily and the other group 
would receive dasatinib 70 mg twice daily.  One study focused on newly diagnosed patients with 
CML.  This study administered 100 mg of dasatinib once daily to one group of patients, with the 
other receiving 400 mg of imatinib once daily. 
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 The comparisons made in these studies were between imatinib and dasatinib.  In the case 
of the two studies utilizing different schedules of dasatinib, the comparison is between not only 
imatinib and dasatinib (as these patients had received imatinib in the past), but also between 
dasatinib 140 mg daily and dasatinib 70 mg twice daily.  The outcomes measured in all three 
trials were overall survival, progression-free survival, and safety profiles (adverse reactions to 
therapy). 
 Information utilized in this review was found using the PubMed database.  Inclusion 
criteria included randomized controlled trials limited to the English language and published in 
peer-reviewed journals.  The key words used used in searches were: “chronic myeloid 
leukemia”, “dasatinib”, and “imatinib”.  Research was conducted by the author.  Articles were 
selected based on relevance to the clinical question and on the importance of outcomes to the 
patient (POEMs).  The inclusion criteria includes that the studies were randomized, controlled, 
prospective, and included patient oriented outcomes (POEMs).  Exclusion criteria included trials 
with patients under the age of 18 and studies that focused exclusively on disease oriented 
outcomes (DOEs).  Ultimately, three studies were found and analyzed.  They included: 1) a 
randomized, open-label, multinational phase 3 trial comparing dasatinib 100 mg daily and 
imatinib 400 mg daily in patients with newly diagnosed CML, 2) a randomized, 2-arm, 
multicenter, open-label, phase 3 trial comparing dasatinib140 mg daily and dasatinib 70 mg 
twice daily in patients with CML who had proven to be imatinib resistant or imatinib intolerant, 
and 3) a randomized, multicenter, open-label, phase 3 trial comparing dasatinib 140 mg daily and 
dasatinib 70 mg twice daily in patients with CML who had proven to be imatinib resistant or 
imatinib intolerant.  A summary of the statistics used include: p-values, RRR, ARR, NNT, NNH. 
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Table 1: Demographics of included studies 
Study Type Number 
of 
patients 
Age Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Kantarjian 
20091 
Randomized, 
2-arm, Phase 
3 trial 
317 18+ Patients 
stopped 
treatment 
with imatinib 
due to 
resistance or 
intolerance, 
Eastern 
Cooperative 
Oncology 
Group 
(ECOG) 
performance 
status score of 
0-2, adequate 
hepatic/renal 
function 
Treatment with 
imatinib, within 7 
days of initiation, 
uncontrolled or 
significant 
cardiovascular 
disease, history of 
a significant 
bleeding disorder 
unrelated to CML, 
any other 
concurrent 
malignancy other 
than CML 
206 Randomized 
to receive 
dasatanib 
140 mg QD 
or dasatinib 
70 mg BID 
 
 
 
 
Kantarjian 
20103 
Randomized, 
Phase 3 trial 
519 18+ Chronic CML 
diagnosed by 
means of 
bone marrow 
biopsy within 
3 months of 
study, no 
previous 
treatments for 
CML, ECOG 
performance 
status score of 
0-2 and 
adequate 
hepatic and 
renal function 
Women who were 
breast-
feeding/pregnant/ 
could potentially 
become pregnant, 
serious 
comorbidities, 
active infections, 
serious 
cardiovascular 
disease, history of 
a significant 
bleeding disorder 
unrelated to CML,  
concurrent 
malignancy other 
than CML 
90 Randomized 
to receive 
dasatinib 
100mg QD 
or imatinib 
400mg QD 
Saglio 
20104 
Randomized, 
Phase 3 trial 
210 16 - 
78 
Resistance or 
intolerance to 
imatinib 
previously, no 
previous 
treatments for 
CML, ECOG 
score of 0-2, 
adequate 
hepatic/renal 
function 
Serious 
comorbidities, 
active infections, 
serious 
cardiovascular 
disease, history of 
a significant 
bleeding disorder 
unrelated to CML, 
concurrent 
malignancy other 
than CML 
198 Randomized 
to receive 
dasatanib 
140 mg QD 
or dasatinib 
70 mg BID 
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RESULTS 
The results were presented in dichotomous form in all three studies analyzed.  In the 
Kantarjian et al 2010 study, the rate of complete cytogenic response by 12 months was 
significantly greater among patients receiving dasatinib than those treated with imatinib (77% 
versus 66%, P=0.007). Progression to the accelerated or blastic phase of CML occurred in 1.9% 
of patients receiving dasatinib, compared to 3.5% of those receiving imatinib.  At 12 months, the 
rates of progression-free survival were similar for patients receiving dasatinib versus imatinib 
(96% vs 97%).  The rates of overall survival were also similar for patients receiving dasatinib 
versus imatinib (97% and 99%). 
Table 2: Efficacy of Dasatinib versus Imatinib in patients with CML 
 Progression to 
accelerated or blastic 
phase of CML 
Progression-free 
survival (at 12 
months) 
Overall survival (at 12 
months) 
Dasatinib 1.9% 96% 97% 
Imatinib 3.5% 97% 99% 
 
The safety profiles revealed greater differences in patient responses to the two drugs.  As 
noted in Table 3, dasatinib had higher rates of hematologic adverse events (neutropenia, 
thrombocytopenia, and anemia).  However, imatinib had higher rates of nonhematologic adverse 
events (fluid retention, diarrhea, nausea, etc.).  The overall rates of discontinuation of therapy 
because of toxic drug effects were 5% with dasatinib and 4% with imatinib.  There was one 
death in each group that was attributed to study treatment, both the result of myocardial 
infarction. 
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Table 3: Adverse events associated with Dasatinib and Imatinib 
 Neutropenia Thrombocytopenia Anemia Fluid 
retention 
Diarrhea Vomiting 
Dasatinib 65% 70% 90% 19% 17% 5% 
Imatinib 58% 62% 84% 42% 17% 10% 
 
 In the Saglio et al study, dasatinib 140 mg daily is compared to dasatinib 70 mg twice 
daily in patients who have already failed imatinib therapy.  The median progression-free survival 
is for the once daily arm and twice daily arm is 3.8 months and 3.7 months respectively.  
However, the 24 month progression-free survival rate was 11% for the once daily regimen and 
18% for the twice daily regimen.  The median overall survival was also similar, with 7.9 months 
in the one daily arm and 7.7 months in the twice daily arm.  The 24 month overall survival rates 
were 24% in the once daily arm and 28% in the twice daily arm.  The majority of deaths were 
considered to be from CML, with 54% in the once daily arm and 41% in the twice daily arm. 
Table 4: Efficacy of Dasatinib 140 mg daily versus Dasatinib 70 mg twice daily in patients with 
imatinib-resistant or intolerant CML 
 Median PFS PFS Rate Median OS OS Rate 
Dasatinib 140 
mg daily 
3.8 months 11% 7.9 months 24% 
Dasatinib 70 mg 
twice daily 
3.7 months 18% 7.7 months 28% 
 
 The more common adverse events were fluid retention, diarrhea, headache, bleeding, 
nausea, fatigue, and rash, and these were typically mild (Grade 1 or 2).  The rates were similar in 
both arms.  Cytopenias also had a similar incidence in both arms. 
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Table 5: Cytopenias associated with Dasatinib 140 mg QD compared to Dasatinib 70 mg BID 
 Neutropenia Thrombocytopenia Anemia Leukocytopenia 
Dasatinib 140 
mg QD 
65/72 (90%) 67/72 (93%) 70/72 (97%) 60/72 (83%) 
Dasatinib 70 mg 
BID 
65/73 (89%) 67/73 (92%) 73/73 (100%) 61/71 (84%) 
 
 In the Katarjian et all 2009 study, dasatinib 140 daily was compared to dasatinib 70 mg 
twice daily in patients with accelerated phase resistant CML or patients intolerant to imatinib.  
The overall survival rates were 78% (95% CI, 71-84%) and 84% (95% CI, 65-79%) for the once 
daily and twice daily groups respectively at 12 months.  At 24 months, the rates were 63% (95% 
CI, 56-71%) for once daily and 72% (95% CI, 65-79%) for twice daily (P=.140).  Among 
patients who died during the study, a similar number died of progressive disease in each of the 
two treatment groups (52% for the once daily group, 43% for the twice daily group; P=.435). 
Table 6: Overall survival rates with Dasatinib 140 mg QD compared to Dasatinib 70 mg BID 
 OS at 12 months OS at 24 months Deaths due to 
progressive disease 
(among total deaths) 
Dasatinib 140 mg QD 78% 63% 52% 
Dasatinib 70 mg BID 84% 72% 43% 
 
 Both dasatinib schedules were relatively well tolerated during the study, with a majority 
of adverse events being mild or moderate (Grades 1 or 2).  The rates of non-hematologic adverse 
events were similar between the two groups, though there was a lower incidence of 
gastrointestinal bleeding seen with the once daily group compared to the twice daily group (8% 
versus 13% respectively, P=.2036).  Pleural effusion rates were also lower in the once daily 
group (20% once daily versus 39% twice daily, P <.001).  The rates of congestive heart failure or 
other cardiac dysfunction were 0% in the once daily group and 3% in the twice daily group.  The 
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most common non-hematologic adverse events included diarrhea, fluid retention, nausea, 
headache, and fatigue.  Incidences of all-grade cytopenia were high and comparable in both 
groups. 
DISCUSSION 
 The randomized controlled trial comparing dasatinib to imatinib in newly diagnosed 
patients with CML showed that with either drug, survival rates are extremely high.  However, 
dasatinib proved to prevent progression to the more severe blastic phase of CML significantly 
better than imatinib.  With dasatinib therapy, progression rates we reduced by about half.  When 
comparing safety profiles, the two drugs had similarly high rates of cytopenias.  Tyrosine kinase 
inhibitors (such as imatinib and dasatinib) prevent ATP binding to BCR-ABL gene expressing 
cells, leading to selective growth disadvantage or apoptotic death of those cells.  Because of this, 
hematologic cell growth is expected to be diminished to some degree.  However, dasatinib had a 
significantly lower rate of non-hematologic adverse events.  The rates of fluid retention are more 
than halved when using dasatinib rather than imatinib, which not only increases quality of life 
but also decreases potentially deadly complications such as congestive heart failure and pleural 
effusion.  There was also a significant decrease in constitutional symptoms such as myalgia, 
vomiting, and diarrhea. 
 The second two randomized controlled trials compared dasatinib 140 mg once daily to 
dasatinib 70 mg twice daily.  This patient population was different than in the first study 
analyzed because they had already discontinued imatinib therapy due to failure of therapy or 
intolerability of adverse effects.  These patients tended to have more progressive disease, and 
therefore, higher morbidity and mortality. 
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 In both studies that compared the two dose schedules, efficacy was quite similar.  This 
was noted in both progression-free survival and overall survival.  However, the once daily 
regimen had improved tolerability.  This is significant when considering both quality of life and 
potential complications in patients treated with dasatinib.  Once daily scheduling showed 
decreased incidences of fluid retention (manifesting itself as superficial edema, pleural effusion, 
pericardial effusion, and congestive heart failure) as well as gastrointestinal bleeding.  These are 
significant sources of morbidity and mortality amongst patients with CML. 
 There were a few limitations to these studies.  The two studies involving dasatinib dosed 
daily or twice daily only focused on patients who had already failed imatinib therapy.  It is not 
known which dose schedule would be more effective or tolerable in a newly diagnosed patient.  
These studies were also not blinded.  Large numbers of patients withdrew from these studies for 
a multitude of reasons, including disease improvement, intolerability to therapy, disease 
progression, and death. 
CONCLUSION 
 Overall, dasatinib does improve outcomes and tolerability in patients with chronic 
myeloid leukemia as compared to imatinib.  While overall survival is similar between the two 
drugs, progression-free survival is significantly improved with dasatinib.  There is also a 
substantial improvement in tolerability when using dasatinib.  This is advantageous not only 
considering patient quality of life, but also morbidity and mortality from complications such as 
pleural effusion, congestive heart failure, and bleeding.  Additionally, many patients discontinue 
imatinib before completing a full course of therapy.  By improving tolerability, patients are more 
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likely to complete the prescribed treatment regimen and, therefore, will receive the maximum 
response. 
 Currently, treatment with dasatinib is only indicated after imatinib therapy has failed.  
The first generation ABL-BCR tyrosine kinase inhibitor is still considered first line therapy, with 
second generation TKIs such as dasatinib being second line therapy.  In the future, it may be 
beneficial to study dasatinib as first line therapy in newly diagnosed CML.  This would allow 
researchers to determine the response to dasatinib in patients who have less progressive disease 
and have not already been exposed to other cytotoxic therapies. 
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